Denali Therapeutics Inc. (DNLI)

NASDAQ: DNLI · Real-Time Price · USD

18.66

-0.02 (-0.11%)

At close: Oct 22, 2026, 4:00 PM EDT

18.64

-0.02 (-0.11%)

Pre-market: Oct 23, 2026, 8:22 AM EDT

Denali Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3.6	-	-	330.53	108.46	48.66
Revenue Growth	-	-	-	204.74%	122.89%	-85.50%
Gross Profit	-397.21	-418.78	-396.44	-93.35	-250.27	-216.69
Operating Income	-541.95	-555.34	-501.88	-196.7	-340.74	-295.75
Net Income	-511.45	-512.54	-422.77	-145.22	-325.99	-290.58
Earnings Per Share	-2.83	-2.97	-2.57	-1.06	-2.60	-2.39
EPS Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '23 Sep 30, 2023	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Takeda Collaboration	-	10	51.92	29.92	27.16	5.93
Sanofi Collaboration	-	25	53.4	15	1.07	20.75
Biogen Collaboration	295.79	295.53	3.15	3.74	307.44	-
Revenue (Total)	-	330.53	-	-	-	-

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	940.01	966.2	1,192	1,035	1,336	1,291
Total Debt	37.69	42.29	54.32	52.24	60.35	64.01
Net Cash (Debt)	902.32	923.91	1,137	982.27	1,276	1,227
Net Cash Growth	-2.92%	-18.77%	15.79%	-23.01%	4.00%	-14.42%
Net Cash Per Share	5.00	5.35	6.92	7.15	10.16	10.10

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-434.04	-412.6	-347.69	-357.99	-244.72	-211.39
Capital Expenditures	-3.42	-9.5	-15.91	-12.94	-17.83	-8.5
Free Cash Flow	-437.46	-422.1	-363.61	-370.93	-262.55	-219.89
Free Cash Flow Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	-	-	-	-28.24%	-230.74%	-
Operating Margin	-15037.38%	-	-	-59.51%	-314.16%	-607.78%
Pretax Margin	-14188.37%	-	-	-43.93%	-300.54%	-598.34%
Profit Margin	-14191.20%	-	-	-43.94%	-300.56%	-597.15%
FCF Margin	-12138.10%	-	-	-112.22%	-242.06%	-451.88%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 23, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Forward PE	-	46.46	46.46	46.46	46.46	46.46
PS Ratio	827.62	-	-	8.97	34.82	111.93